Detalles de la búsqueda
1.
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. / Effektivnost' i bezopasnost' dvukhletnei terapii divozilimabom u patsientov s rasseyannym sklerozom v ramkakh randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-4/MIRANTIBUS.
Zh Nevrol Psikhiatr Im S S Korsakova
; 124(4): 86-96, 2024.
Artículo
en Ruso
| MEDLINE | ID: mdl-38676683
2.
[Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial]. / Lechenie kognitivnykh, povedencheskikh i psikhicheskikh narushenii u patsientov s sosudistoi dementsiei: rezul'taty mnogotsentrovogo randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(7): 41-49, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37490664
3.
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. / Effektivnost' i bezopasnost' 48 nedel'nogo primeneniya monoklonal'nogo antitela protiv CD20 divozilimaba u patsientov s rasseyannym sklerozom: rezul'taty randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-4/MIRANTIBUS.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(7. Vyp. 2): 43-52, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37560833
4.
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]. / Effektivnost' i bezopasnost' 24 nedel' primeneniya divozilimaba sredi patsientov s rasseyannym sklerozom v ramkakh randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-2.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(4): 37-47, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37084363
5.
[Efficacy and safety of sampeginterferon ß-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial]. / Effektivnost' i bezopasnost' sampeginterferona ß-1a dlya lecheniya remittiruyushchego rasseyannogo skleroza: rezul'taty 52-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 122(1): 62-71, 2022.
Artículo
en Ruso
| MEDLINE | ID: mdl-35175704
6.
[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis]. / Novyi pegilirovannyi interferon beta-1a (sampéginterferon beta-1a, BCD-054) v terapii remittiruiushchego rasseiannogo skleroza.
Zh Nevrol Psikhiatr Im S S Korsakova
; 119(10. Vyp. 2): 100-109, 2019.
Artículo
en Ruso
| MEDLINE | ID: mdl-31934995
7.
The odor specificities of a subset of olfactory receptor neurons are governed by Acj6, a POU-domain transcription factor.
Neuron
; 22(2): 339-47, 1999 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-10069339
8.
Memory dysfunction and autonomic neuropathy in non-insulin-dependent (type 2) diabetic patients.
Diabetes Res Clin Pract
; 30(2): 101-10, 1995 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-8833630
Resultados
1 -
8
de 8
1
Próxima >
>>